Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

This phase 1/2 study is the first prospective evaluation of lenalidomide-bortezomib-dexamethasone in front-line myeloma. Patients (N = 66) received 3-week cycles (n = 8) of bortezomib 1.0 or 1.3 mg/m(2) (days 1, 4, 8, 11), lenalidomide 15 to 25 mg (days 1-14), and dexamethasone 40 or 20 mg (days 1,...

詳細記述

保存先:
書誌詳細
主要な著者: Richardson, Paul G., Weller, Edie, Lonial, Sagar, Jakubowiak, Andrzej J., Jagannath, Sundar, Raje, Noopur S., Avigan, David E., Xie, Wanling, Ghobrial, Irene M., Schlossman, Robert L., Mazumder, Amitabha, Munshi, Nikhil C., Vesole, David H., Joyce, Robin, Kaufman, Jonathan L., Doss, Deborah, Warren, Diane L., Lunde, Laura E., Kaster, Sarah, DeLaney, Carol, Hideshima, Teru, Mitsiades, Constantine S., Knight, Robert, Esseltine, Dixie-Lee, Anderson, Kenneth C.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2010
主題:
Plenary Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3324254/
https://ncbi.nlm.nih.gov/pubmed/20385792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-02-268862
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料